The Pharmaceutical Journal
Vol 272 No 7297 p532
1 May 2004

This article
Reprint   Photocopy

  Acrobat Reader

News summary

Weak evidence for children's migraine treatment

Published evidence supporting the use of migraine treatments in children is weak, according to the April issue of Drug and Therapeutics Bulletin (2004;42:25).

Noting that there is only weak evidence that nasal sumatriptan relieves migraine in those aged 12–17 years and that evidence is also weak for the use of pizotifen or propranolol as prophylaxis against repeated attacks, it concludes that for acute attacks of migraine, paracetamol or ibuprofen, combined with an anti-emetic if necessary, is usually sufficient.